Observational studyCancer treatment and research communications2025

Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non-small-cell lung cancer.

Kibum Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.